Home/Filings/4/0001610717-24-000478
4//SEC Filing

Lenz Robert A. 4

Accession 0001610717-24-000478

CIK 0001885522other

Filed

Sep 15, 8:00 PM ET

Accepted

Sep 16, 4:05 PM ET

Size

5.2 KB

Accession

0001610717-24-000478

Insider Transaction Report

Form 4
Period: 2024-09-12
Lenz Robert A.
Head of R&D
Transactions
  • Sale

    Common Stock

    2024-09-12$11.43/sh32,948$376,665369,993 total
Footnotes (2)
  • [F1]Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on June 12, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.
  • [F2]This transaction was executed in multiple trades in prices ranging from $11.22 to $11.6050, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Documents

1 file

Issuer

Neumora Therapeutics, Inc.

CIK 0001885522

Entity typeother

Related Parties

1
  • filerCIK 0001992908

Filing Metadata

Form type
4
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 4:05 PM ET
Size
5.2 KB